Treating Opioid Dependence with Buprenorphine in the Safety Net: Critical Learning from Clinical Data

  • Traci R. Rieckmann
  • Nicholas Gideonse
  • Amanda Risser
  • Jennifer E. DeVoe
  • Amanda J. Abraham
Article
  • 91 Downloads

Abstract

Research has examined the safety, efficacy, feasibility, and cost-effectiveness of buprenorphine for the treatment of opioid dependence, but few studies have examined patient and provider experiences, especially in community health centers. Using de-identified electronic health record system (EHRS) data from 70 OCHIN community health centers (n = 1825), this cross-sectional analysis compared the demographics, comorbidities, and service utilization of patients receiving buprenorphine to those not receiving medication-assisted treatment (MAT). Compared to non-MAT patients, buprenorphine patients were younger and less likely to be Hispanic or live in poverty. Buprenorphine patients were less likely to have Medicaid insurance coverage, more likely to self-pay, and have private insurance coverage. Buprenorphine patients were less likely to have problem medical comorbidities or be coprescribed high-risk medications. It is important for providers, clinic administrators, and patients to understand the clinical application of medications for opioid dependence to ensure safe and effective care within safety net clinics.

References

  1. 1.
    Center for Disease Control. Wide-ranging online data for epidemiologic research (WONDER). Atlanta, GA: CDC, National Center for Health Statistics; 2016. Available at http://wonder.cdc.gov.Google Scholar
  2. 2.
    Substance Abuse and Mental Health Services Association. Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health. (HHS Publication No. SMA 15–4927, NSDUH Series H-50), Rockville, MD, 2014.Google Scholar
  3. 3.
    Buck JA. The looming expansion and transformation of public substance abuse treatment under the affordable care act. Health Aff 2011 Aug;30(8):1402–10. doi: 10.1377/hlthaff.2011.0480.CrossRefGoogle Scholar
  4. 4.
    Shortell SM, Casalino LP, Fisher ES. How the center for Medicare and Medicaid innovation should test accountable care organizations. Health Aff 2010;29(7): 1293–8.CrossRefGoogle Scholar
  5. 5.
    Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: The NIDA clinical trials network field experience. Am J Addict 2004;13 Suppl 1:S42–66.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Anton RF, Moak DH, Waid LR, et al. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am J Psychiatr 1999 Nov;156(11):1758–64.PubMedGoogle Scholar
  7. 7.
    Cunningham C, Giovanniello A, Sacajiu G, et al. Buprenorphine treatment in an urban community health center: What to expect. Fam Med 2008;40(7):500–6.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Fiellin DA, Pantalon MV, Pakes JP, et al. Treatment of heroin dependence with buprenorphine in primary care. Am J Drug Alcohol Abuse 2002;28(2): 231–41.CrossRefPubMedGoogle Scholar
  9. 9.
    Johnson R, Chutuape M, Strain EC, et al. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000;343(18): 1290–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Ling W, Charuvastra C, Collins J, et al. Buprenorphine maintenance treatment of opiate dependence: A multicenter, randomized clinical trial. Addiction 1998;93(4): 475–86.CrossRefPubMedGoogle Scholar
  11. 11.
    Monti P, Rohsenow D, Swift RM, et al. Naltrexone and cue exposure with coping and communication skills training for alcoholics: Treatment process and 1-year outcomes. Alcohol Clin Exp Res 2001;25(11): 1634–47.CrossRefPubMedGoogle Scholar
  12. 12.
    Stein M, Cioe P, Friedmann P. Buprenorphine retention in primary care. J Gen Intern Med 2005;20(11): 1038–41.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Arch Gen Psychiatry 2011;68(12): 1238–46.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Comer SD, Walker EA, Collins ED. Buprenorphine/naloxone reduces the reinforcing and subjective effects of heroin in heroin-dependent volunteers. Psychopharmacology 2005;181(4): 664–75.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine in opioid-related disorders. Can Fam Physician 2012;58(1):37–41.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Ling W, Jacobs P, Hillhouse M, et al. From research to real world: Buprenorphine in the decade of the Clinical Trials Network. J Subst Abus Treat 2010;38(S1): S53–60.CrossRefGoogle Scholar
  17. 17.
    Fiellin DA, Friedland GH, Gourevitch MN. Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis 2006;43(S4): S173–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Kahan M, Srivastava A, Ordean A, et al. Buprenorphine: new treatment of opioid addiction in primary care. Can Fam Physician 2011;57(3): 281–9.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Awgu E, Magura S, Rosenblum A. Heroin-dependent inmates’ experiences with buprenorphine or methadone maintenance. J Psychoactive Drugs 2010 Sep;42(3):339–46.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Pinto H, Maskrey V, Swift L, et al. The SUMMIT trial: A field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abus Treat 2010;39(4): 340–52.CrossRefGoogle Scholar
  21. 21.
    Ridge G, Gossop M, Lintzeris N. Factors associated with the prescribing of buprenorphine or methadone for treatment of opiate dependence. J Subst Abus Treat 2009;37(1): 95–100.CrossRefGoogle Scholar
  22. 22.
    Polsky D, Glick HA, Yang J, et al. Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial. Addiction 2010;105(9): 1616–24.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    American Society of Addiction Medicine. 2016 The National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. Chevy Chase, MDGoogle Scholar
  24. 24.
    Center for Substance Abuse Treatment. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP). Series 40, DHHS Publication No. (SMA) 04–3939. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2004.Google Scholar
  25. 25.
    Centers for Disease Control and Prevention. Planning and Implementing Screening and Brief Intervention for Risky Alcohol Use: A Step-by-Step Guide for Primary Care Practices. Atlanta, Georgia: Centers for Disease Control and Prevention, National Center on Birth Defects and Developmental Disabilities, 2014.Google Scholar
  26. 26.
    Baldini A, Von Korff M, Lin EH. 2012 A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. The Primary Care Companion for CNS Disorders. 14(3)Google Scholar
  27. 27.
    Costenbader EC, Zule WA, Coomes CM. The impact of illicit drug use and harmful drinking on quality of life among injection drug users at high risk for Hepatitis C infection. Drug Alcohol Depend 2007;89(2–3): 251–58.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Haddad MW, Zelenev A, Altice FL. Integrating buprenorphine maintenance therapy into federally qualified health centers: Real-world substance abuse treatment outcomes. Drug Alcohol Depend 2013;131(1–2): 127–35. doi: 10.1016/j.drugalcdep.2012.12.008.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Howard AA, Hoover DR, Anastos K, et al. The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the women’s interagency HIV study. J Acquir Immune Defic Syndr 2010;54(2): 152–59.PubMedPubMedCentralGoogle Scholar
  30. 30.
    Modesto-Lowe V, Brooks D, Petry N. Methadone deaths: Risk factors in pain and addiction populations. J Gen Intern Med 2010;25(4): 305–09. doi: 10.1007/s11606-009-1225-0.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Rowe TA, Jacapraro JS, Rastegar DA. Entry into primary care-based buprenorphine treatment is associated with identification and treatment of other chronic medical problems. Addiction Science and Clinical Practice 2012;7(22): 1–5.Google Scholar
  32. 32.
    Batki SL, Canfield KM, Ploutz-Snyder R. Psychiatric and substance use disorders among methadone maintenance patients with chronic hepatitis C infection: Effects on eligibility for hepatitis C treatment. Am J Addict 2011 Jul-Aug;20(4):312–8. doi: 10.1111/j.1521-0391.2011.00139.x.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Grella CE, Karno MP, Warda US, et al. Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav 2009;34(6–7): 498–504.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Bogdanowicz KM, Stewart R, Broadbent M, et al. Double trouble: Psychiatric comorbidity and opioid addiction-all-cause and cause-specific mortality. Drug Alcohol Depend 2015; 148: 85–92.CrossRefPubMedGoogle Scholar
  35. 35.
    Mannelli P, Wu L-T, Peindl KS, Gorelick DA. Smoking and Opioid Detoxification: Behavioral Changes and Response to Treatment. Nicotine Tob Res 2013;15(10):1705–1713.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Saunders SA, Democratis J, Martin J, et al. Intravenous drug abuse and type 1 diabetes: Financial and healthcare implications. Diabet Med 2004;21(12): 1269–73.CrossRefPubMedGoogle Scholar
  37. 37.
    Stein MD. Medical consequences of substance abuse. The Psychiatry Clinics of North America 1999;22(2): 351–70.CrossRefGoogle Scholar
  38. 38.
    Jones JD, Mogali S, Comer SD. Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend 2012;125(1–2): 8–18.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Lintzeris N, Nielsen S. Benzodiazepines, methadone, and buprenorphine: Interactions and clinical management. Am J Addict 2009;19(1): 59–72. doi: 10.1111/j.1521-0391.2009.00007.x.CrossRefGoogle Scholar
  40. 40.
    McCance-Katz EF, Sullivan L, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: A review. Am J Addict 2010;19(1): 4–16.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    McCance-Katz EF, Moody DE, Morse GD, et al. Interaction between buprenorphine and atazanavir or atazanavir/ritonavir. Drug Alcohol Depend 2007;91(2–3): 269–78.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Tai B, McLellan AT. Integrating information on substance use disorders into electronic health record systems. J Subst Abus Treat 2012;43(1): 12–9.CrossRefGoogle Scholar
  43. 43.
    Fiellin DA, O’Connor PG. New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002;137(8): 688–92.CrossRefPubMedGoogle Scholar
  44. 44.
    Mintzer IL, Eisenberg M, Terra M, et al. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med 2007;5(2): 146–50.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Substance Abuse and Mental Health Services Administration. Alcohol and Drug Services Study (ADSS). The National Treatment System: Outpatient Methadone Facilities. Rockville, MD: Office of Applied Studies, 2004.Google Scholar
  46. 46.
    Shah S, Diwan S. Methadone: Does stigma play a role as a barrier to treatment of chronic pain? Pain Physician 2010;13(3): 289–93.PubMedGoogle Scholar
  47. 47.
    Cunningham C, Sohler NL, McCoy K, et al. Attending physicians’ and residents’ attitudes and beliefs about prescribing buprenorphine at an urban teaching hospital. Fam Med 2006;38(5): 336–40.PubMedGoogle Scholar
  48. 48.
    Felice AM, Kouimtsidis C. Improving services offered by GPs to patients with drug addiction. Ment Health Pract 2012;16(1):19–22.CrossRefGoogle Scholar
  49. 49.
    Substance Abuse and Mental Health Services Administration. National Survey of Substance Abuse Treatment Services (N-SSATS): 2014. Data on Substance Abuse Treatment Facilities. BHSIS Series S-79, HHS Publication No. (SMA) 16-4963. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2015.Google Scholar
  50. 50.
    Substance Abuse and Mental Health Services Administration. The determinations report: a report on the physician waiver program established by the drug addiction treatment act of 2000 (“DATA”). Rockville, MD: U.S. Department of Health and Human Services, 2006.Google Scholar
  51. 51.
    Netherland J, Botsko M, Egan JE, et al. Factors affecting willingness to provide buprenorphine treatment. J Subst Abus Treat 2009;36(3): 244–51.CrossRefGoogle Scholar
  52. 52.
    Albright J, Ciaverelli R, Essex A, et al. Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment. J Addict Med 2010 Dec;4(4):197–203. doi: 10.1097/ADM.0b013e3181c816f3.CrossRefPubMedGoogle Scholar
  53. 53.
    Center for Substance Abuse Treatment. Medication-assisted treatment for opioid addiction in opioid treatment programs. Rockville, MD: Substance Abuse and Mental Health Administration, 2005.Google Scholar
  54. 54.
    Kissin W, McLeod C, Sonnefeld J, et al. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006;25(4): 91–103.CrossRefPubMedGoogle Scholar
  55. 55.
    Knudsen HK, Ducharme LJ, Roman PM. The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug Alcohol Depend 2007;87(2–3): 164–74.CrossRefPubMedGoogle Scholar
  56. 56.
    Jones CM, Campopiano M, Baldwin G, et al. National and state treatment need and capacity for opioid agonist medication assisted treatment. Am J Public Health 2015;105(8): 55–63.CrossRefGoogle Scholar
  57. 57.
    Clark RE, Samnaliev M, Baxter JD, et al. The evidence doesn’t justify steps by state Medicaid programs to restrict opioid addiction treatment with buprenorphine. Health Aff 2011;30(8): 1425–33.CrossRefGoogle Scholar
  58. 58.
    StataCorp. Release 13: Statistical software [computer program]. College Station, TX: StataCorp LP, 2013.Google Scholar
  59. 59.
    Sullivan L, Chawarski M, O'Connor P, et al. The practice of office-based buprenorphine treatment of opioid dependence: Is it associated with new patients entering into treatment? Drug Alcohol Depend 2005;79(1): 113–6.CrossRefPubMedGoogle Scholar
  60. 60.
    Guerrero EG, Marsh JC, Khachikian T, et al. Disparities in Latino substance use, service use, and treatment: Implications for culturally and evidence-based interventions under health care reform. Drug Alcohol Depend 2013;133(3):805–13. doi: 10.1016/j.drugalcdep.2013.07.027.CrossRefPubMedGoogle Scholar
  61. 61.
    Hartung D, McCarty D, Fu R, et al. Extended-release Naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. J Subst Abus Treat 2014;47(2): 113–121. doi: 10.1016/j.jsat.2014.03.007 CrossRefGoogle Scholar
  62. 62.
    Tkacz J, Volpicelli J, Un H, et al. Relationship between buprenorphine adherence and health service utilization and costs among opioid dependent patients. J Subst Abus Treat 2014;46(4): 456–462. doi: 10.1016/j.jsat.2013.10.014.CrossRefGoogle Scholar
  63. 63.
    Hutchinson E, Catlin M, Andrilla CH, et al. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med 2014;12(2):128–133. doi: 10.1370/afm.1595.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Duncan LG, Mendoza S, Hansen H. Buprenorphine maintenance for opioid dependence in public sector healthcare: Benefits and barriers. Journal of Addiction Medicine and Therapeutic Science 2015;1(2):31–36.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    DeFlavio JR, Rolin SA, Nordstrom BR, Kazal LA Jr. Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians. Rural Remote Health 2015;15:3019.PubMedGoogle Scholar
  66. 66.
    Baxter JD, Clark RE, Samnaliev M, et al. Factors associated with Medicaid patients’ access to buprenorphine treatment. J Subst Abus Treat 2011 Jul;41(1):88–96. doi: 10.1016/j.jsat.2011.02.002.CrossRefGoogle Scholar
  67. 67.
    Druss BG, Von Esenwein SA. Improving general medical care for persons with mental and addictive disorders: Systematic review. Gen Hosp Psychiatry 2006;28(2): 145–53.CrossRefPubMedGoogle Scholar

Copyright information

© National Council for Behavioral Health 2017

Authors and Affiliations

  • Traci R. Rieckmann
    • 1
  • Nicholas Gideonse
    • 2
  • Amanda Risser
    • 2
  • Jennifer E. DeVoe
    • 3
  • Amanda J. Abraham
    • 4
  1. 1.OHSU-PSU School of Public HealthOregon Health & Science UniversityPortlandUSA
  2. 2.Department of Family MedicineOregon Health & Science UniversityPortlandUSA
  3. 3.OCHIN Community Health Information NetworkPortlandUSA
  4. 4.Department of Public Administration and PolicyUniversity of GeorgiaAthensUSA

Personalised recommendations